Effect OF Ranitidine on Single Dose and Steady State Pharmacokinetics of Metformin

School of Pharmaceutical Sciences Vels University0 个研究点目标入组 17 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Newly diagnosed with type II diabetes mellitus (as per standard diagnostic criterion).
•2. Willing to provide a written informed consent and return for followup after four weeks.

•1. Patients whose glomerular filtration rate is less than 60mL/min.
•2. Patients with life threatening conditions including malignancies with or without CNS involvement, known cases of coronary artery disease, recent history of STEMI/NSTEMI, ischemic or hemorrhagic stroke, recent history of head trauma or any major physical injury and any other underlying condition which may predispose the subject to risk of serious adverse events.
•3. Patients on medication known to alter metformin pharmacokinetics.
•4. Patients with severe anemia in whom withdrawal of blood by venipuncture is not recommended.
•5. Patients who are mentally unstable with underlying psychiatric illness.
•6. Pregnant and lactating women.
•7. Patients who are unwilling either to provide a written informed consent or return for follow up after four weeks.

发起方

School of Pharmaceutical Sciences Vels University